AACR: Antibody-Drug Conjugate Shows Promise in Platinum-Resistant Ovarian Cancer
A novel therapy has shown activity in the treatment of difficult-to-treat, advanced, platinum-resistant ovarian cancer. The drug, DMUC5754A, is part of a new class of drugs called antibody-drug conjugates. (Source: Cancer Network)
Source: Cancer Network - April 9, 2013 Category: Cancer & Oncology Source Type: news

AACR: Targeting Luminal Breast Cancer Stem Cells With Trastuzumab Blocks Metastatic Growth in Preclinical Models
Trastuzumab (Herceptin) therapy may be useful for the treatment of luminal breast cancer stem cells, preventing them from growing into macrometastases, according to preclinical results presented at the 2013 American Association for Cancer Research Annual Meeting. (Source: Cancer Network)
Source: Cancer Network - April 9, 2013 Category: Cancer & Oncology Source Type: news

AACR: Promising Phase I Clinical Data With Pan-AKT Inhibitor in Solid Tumors
Different dosing schedules of the pan-AKT inhibitor AZD5363 revealed key details about maximum tolerable dosages, and biochemical efficacy was suggested by analyzing biomarkers, according to the results of a phase I study presented at the 2013 annual meeting of the American Association of Cancer Research. (Source: Cancer Network)
Source: Cancer Network - April 9, 2013 Category: Cancer & Oncology Source Type: news

AACR: Anti-PI3K/MEK Inhibitor Targeted Therapy Combo Shows Activity
A new agent, SAR245409, that simultaneous targets two pathways important for the growth of tumors--the PI3K/mTOR pathway and the MAPK pathway--has shown activity in advanced solid tumors, according to results from a phase I trial presented at the American Association for Cancer Research Annual Meeting. (Source: Cancer Network)
Source: Cancer Network - April 9, 2013 Category: Cancer & Oncology Source Type: news

AACR: T-DM1 Most Effective in Breast Cancer Patients With High HER2 Expression
Researchers participating in the phase III EMILIA trial have identified tumor biomarkers that can identify patients that are more likely to benefit from T-DM1. In the trial, women whose tumors had higher HER2 expression were most likely to benefit from the therapy. (Source: Cancer Network)
Source: Cancer Network - April 8, 2013 Category: Cancer & Oncology Source Type: news

AACR: Triple-Negative Breast Cancer—Utilizing Biomarkers for Better Therapeutic Strategies
The breast cancer field now understands that triple-negative breast cancer (TNBC) comprises a heterogeneous set of tumor types. How to parse TNBC into distinct subtypes? One current approach is to study subtypes of TNBC and target their specific features. Another way is to specifically target the genetics of these cancers. (Source: Cancer Network)
Source: Cancer Network - April 8, 2013 Category: Cancer & Oncology Source Type: news

AACR: Androgen Deprivation Therapy Resistance in Prostate Cancer--A Hypothesis
Targeting prostate cancer stem cells may be a method of treating prostate cancer while avoiding the development of resistance to androgen deprivation therapy, according to preclinical results presented at the annual meeting of the American Association for Cancer Research. (Source: Cancer Network)
Source: Cancer Network - April 8, 2013 Category: Cancer & Oncology Source Type: news

Higher Soy Intake Associated With Longer Survival in Lung Cancer
Women with lung cancer who ate more soy prediagnosis appear to survive longer than patients who ate fewer soy-based foods, according to a new Chinese study. (Source: Cancer Network)
Source: Cancer Network - April 8, 2013 Category: Cancer & Oncology Source Type: news

Conflicts of Interest in Medicine: What About Ties to Payers?
Recently, the US government released new “Sunshine” standards requiring more rigorous disclosure of potential financial conflicts of interest in medicine. Such new standards are driven by revelations of misdeeds on the part of pharmaceutical and device manufacturers. (Source: Cancer Network)
Source: Cancer Network - April 5, 2013 Category: Cancer & Oncology Source Type: news

AACR: Lung Cancer Therapy Innovations
In this interview, ahead of the AACR annual meeting, we speak with Dr. Julie Brahmer, of Johns Hopkins School of Medicine, who is giving a presentation on immunotherapy in lung cancer, and is one of the clinical investigators of the extensive phase I trial of the anti–PD-1 antibody nivolumab. (Source: Cancer Network)
Source: Cancer Network - April 5, 2013 Category: Cancer & Oncology Source Type: news

Potential Target for Castration-Resistant Prostate Cancer Discovered
Researchers have identified a mechanism by which prostate cancer resists hormonal therapy to develop into castration-resistant prostate cancer (CRPC). The protein SIAH2 keeps a fraction of androgen receptors constitutively active in prostate cancer cells. (Source: Cancer Network)
Source: Cancer Network - April 4, 2013 Category: Cancer & Oncology Source Type: news

FDA Approves Regorafenib (Stivarga) for GIST
The US Food and Drug Administration approved the multi-kinase inhibitor regorafenib (Stivarga) yesterday, for the treatment of patients with unresectable metastatic gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib. (Source: Cancer Network)
Source: Cancer Network - February 27, 2013 Category: Cancer & Oncology Source Type: news

Targeting GFI1 May Improve Prognosis in ALL, Study Suggests
Findings of a newly published study by an international team of researchers suggest that targeting growth factor independence 1 (GFI1) may improve the prognosis of patients with T-cell acute lymphoblastic leukemia or other lymphoid leukemias. (Source: Cancer Network)
Source: Cancer Network - February 26, 2013 Category: Cancer & Oncology Source Type: news

Latest Advances and Challenges in Radiation Oncology
Along with chemotherapy and surgery, radiation therapy remains one of the three main treatments for cancer. A new article in Science Translational Medicine reviews the recent advances and current challenges in radiation oncology today. (Source: Cancer Network)
Source: Cancer Network - February 25, 2013 Category: Cancer & Oncology Source Type: news

Testicular Mass Discovered in 28-Year-Old Patient
A 28-year-old man presents with testicular pain of several weeks duration. Physical examination discloses the presence of a right testicular mass. Orchiectomy is performed. What is your Diagnosis? (Source: Cancer Network)
Source: Cancer Network - February 25, 2013 Category: Cancer & Oncology Source Type: news

Latest Advances and Challenges in Radiation Oncology
Along with chemotherapy and surgery, radiation therapy remains one of the three main treatments for cancer. A new article in Science Translational Medicine reviews the recent advances and current challenges in radiation oncology today. (Source: Cancer Network)
Source: Cancer Network - February 25, 2013 Category: Cancer & Oncology Source Type: news

BCL2 Inhibitors Selectively Target Leukemia Stem Cells
Researchers from the University of Rochester have identified BCL2 inhibitors as potential leukemia stem cell-targeting agents, demonstrating that two such inhibitors killed inactive and metabolically slower leukemia stem cells. (Source: Cancer Network)
Source: Cancer Network - February 23, 2013 Category: Cancer & Oncology Source Type: news

FDA Approves T-DM1 (Kadcyla) for HER2-Positive Breast Cancer
The US Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla) for the treatment of patients with metastatic HER2-positive breast cancer earlier today. (Source: Cancer Network)
Source: Cancer Network - February 22, 2013 Category: Cancer & Oncology Source Type: news

Status of HPV-Related Cancers and Vaccination Trends
In this interview we discuss HPV-associated cancers, which are on the rise, and the low vaccination coverage for HPV with Edgar Simard, PhD, MPH, senior epidemiologist of surveillance research, who studies the impact of prevention and screening on cancer incidence at the American Cancer Society. (Source: Cancer Network)
Source: Cancer Network - February 21, 2013 Category: Cancer & Oncology Source Type: news

As CML Drugs Improve, Earlier Surrogate Outcome Markers Needed
As patients and physicians gain experience with a second generation of relatively effective therapies for chronic myeloid leukemia, there is increasing need to quickly understand who will fare best with these drugs. (Source: Cancer Network)
Source: Cancer Network - February 20, 2013 Category: Cancer & Oncology Source Type: news

HER Signaling May Explain Chemo Resistance in Lung Cancer
Increased levels of human epidermal growth factor receptor (HER) may be the key to chemotherapy resistance in non–small-cell lung cancer (NSCLC), according to a new study. (Source: Cancer Network)
Source: Cancer Network - February 20, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: MVAC Safe Alternative for Neoadjuvant Treatment of Invasive Bladder Cancer
In a trial of 64 patients, neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) had promising results in the treatment of muscle-invasive bladder cancer. (Source: Cancer Network)
Source: Cancer Network - February 19, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: Axitinib Fails to Meet Endpoint vs Sorafenib for First-Line RCC Therapy
A trial comparing axitinib to sorafenib as first-line therapy for metastatic renal cell carcinoma showed a statistically significant improvement in progression-free survival for the drug; however, the difference failed to meet the phase III trial’s prespecified significance level of 0.025. (Source: Cancer Network)
Source: Cancer Network - February 19, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: Clinical Staging in Bladder Cancer Inaccurate Nearly Half of the Time
The use of presurgical characteristics to assign the clinical stage of a patient with bladder cancer was found to be highly inaccurate with a clinical/pathological stage discrepancy rate of 47.8% found in a large sample of patients taken from the National Cancer Data Base between 1998 and 2009. (Source: Cancer Network)
Source: Cancer Network - February 19, 2013 Category: Cancer & Oncology Source Type: news

Targeting Leukemic Stem Cells in Marrow Could Stave Off TKI Resistance
New research suggests that a novel, investigative drug could help alleviate some of the resistance to tyrosine kinase inhibitor treatment seen in chronic myeloid leukemia (CML). The drug, a pan-BCL2 inhibitor called sabutoclax, could sensitize malignant leukemic stem cells in the bone marrow niche to TKI treatment. (Source: Cancer Network)
Source: Cancer Network - February 19, 2013 Category: Cancer & Oncology Source Type: news

Sorafenib for RCC Well-Tolerated in Older Patients
Results from a retrospective analysis indicate that the use of the antiangiogenic, VEGF inhibitor sorafenib for the treatment of advanced renal cell carcinoma was well tolerated in patients aged 65 years or older. (Source: Cancer Network)
Source: Cancer Network - February 18, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: Adjuvant Radiotherapy Post Prostatectomy Still Safe at 10 Years
The use of adjuvant radiotherapy in patients with pT3 prostate cancer subsequent to radical prostatectomy is safe, according to 10-year follow-up results presented at the 2013 Genitourinary Cancers Symposium. (Source: Cancer Network)
Source: Cancer Network - February 16, 2013 Category: Cancer & Oncology Source Type: news

Ethical Challenges in Oncology, Explored Through a Series of Vignettes
In this article, we have chosen to focus on three ethical challenges that we believe practicing oncologists might commonly encounter with their patients. The ethical dilemmas are presented in a case-based approach in the hope of better joining the ethical theory to clinical practice. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Rationing Healthcare: Who's Responsible?
To place responsibility for rationing chemotherapeutics on the oncologist not only increases his or her emotional burden, but it also strains the doctor-patient relationship. We should not allow oncologists to become bedside healthcare rationers simply because no one else wants to do the job. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

A Common Theme Among Ethical Issues in Oncology: The Need to Individualize Advanced Cancer Care
Oncologists would be well advised to consider their obligations to the patient, as well as other stakeholders, and be prepared to resolve potential conflicts that go beyond the focus of their clinical training. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

"OMG, How Long Is This Going to Take?"
It is hard to realize that an elderly patient's visit to you is likely the only trip outside his or her apartment for the week and the only contact with someone other than family or an aide. Doctor visits sometimes become the elderly's primary contact with the larger world. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Diffuse Large B-Cell Non-Hodgkin Lymphoma in the Very Elderly: Challenges and Solutions
In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered by investigators who are conducting studies in this patient population. We conclude by proposing an algorithm to help clinicians determine the optimal therapeutic strategy for treatment of DLBCL in very elderly patients. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Diffuse Large B-Cell Lymphoma in the Very Elderly: The Case for Refining Our Clinical Trials
Further prospective clinical trials in very elderly patients with DLBCL are clearly needed. Complementing the growing need for such trials, an evolving clinical trial infrastructure, geriatric oncology support, and novel therapeutics are making such studies feasible in the current era. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Diffuse Large B-Cell Lymphoma in the Elderly: Leaving Our Old Way(s) Behind?
Patients should ideally undergo very thoughtful evaluation with tools such as the comprehensive geriatric assessment or something similar that will give the treating physician the best estimate of therapy tolerance. Once therapy is initiated, very frequent monitoring is useful for providing early support of toxicity and for most promptly and effectively informing appropriate dose adjustments to ensure optimal dosing. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Intraoperative Radiotherapy for Breast Cancer: Its Perceived Simplicity
With many centers seeking to adopt IORT, there are licensing, proctoring, staffing, technical support, and reimbursement issues that need to be considered. We have reviewed the current international experience and describe one community cancer center’s experience with initiating an IORT breast cancer program. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

On the Road to Intraoperative Radiotherapy: More 'Proceed With Caution' Signs
The prospect of even more compressed radiotherapy options for women requiring adjuvant breast radiotherapy is exciting. However, we urge readers to be cautious in their interpretation of the current intraoperative literature as they implement their programs. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Intraoperative Radiotherapy for Breast Cancer: Deceptively Simple?
Due to the fact that we do not have mature long-term data regarding efficacy, we are still several years away from declaring IORT to be a viable alternative to the current standard of care in patients with early-stage breast cancer. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: In Prostate Cancer, Shorter Androgen Blockade Just As Effective
Physicians treating men with high-risk prostate cancer can safely reduce the duration of androgen blockade given in combination with pelvic radiation from 36 months to 18 months without compromising outcomes, including survival. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Abdominal Mass Found in 53-Year-Old Patient
A 53-year-old woman presented with abominal pain. Physical examination and radiographic imaging shows the presence of an abdominal mass. Biopsy of the mass was performed. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: In Two Trials, Targeted Therapies Miss Mark for Prostate Cancer
In two phase III studies—READY and VENICE—targeted agents combined with standard first-line chemotherapy failed to increase overall survival for men with metastatic castration-resistant prostate cancer. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: Early Treatment and Active Surveillance of Prostate Cancer Patients
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

Surveillance Safe for Small Kidney Tumors in Older Patients
New data suggest that surveillance of patients with small kidney tumors may be a safe alternative to surgery, especially in older patients or those with comorbid conditions. (Source: Cancer Network)
Source: Cancer Network - February 14, 2013 Category: Cancer & Oncology Source Type: news

ASCO GU: Surveillance Safe for Small Kidney Tumors in Older Patients
New data suggest that surveillance of patients with small kidney tumors may be a safe alternative to surgery, especially in older patients or those with comorbid conditions. (Source: Cancer Network)
Source: Cancer Network - February 13, 2013 Category: Cancer & Oncology Source Type: news

MicroRNA-18b May Act as Tumor Suppressor in Melanoma
Preclinical analyses have indicated that microRNA-18b may have a role as a tumor suppressor, has the potential to be a biomarker for melanoma, and its overexpression may be a novel therapeutic strategy for the treatment of melanoma. (Source: Cancer Network)
Source: Cancer Network - February 12, 2013 Category: Cancer & Oncology Source Type: news

Sunitinib Does Not Accelerate Tumor Growth Post-Therapy
In a new study, researchers show that the TKI sunitinib, FDA-approved for advanced renal cell carcinoma, does not result in accelerated growth of kidney tumors after discontinuing treatment. (Source: Cancer Network)
Source: Cancer Network - February 12, 2013 Category: Cancer & Oncology Source Type: news

FDA Approves Pomalidomide (Pomalyst) for Multiple Myeloma
The US Food and Drug Administration (FDA) approved pomalidomide (Pomalyst) last week to treat patients with relapsed or refractory multiple myeloma. (Source: Cancer Network)
Source: Cancer Network - February 11, 2013 Category: Cancer & Oncology Source Type: news

Are We Treaters, Passers, or Doctors?
As often as not, the decision whether to treat or deny treatment to any elderly patient with cancer is a result of an oncologist’s impression of the individual person’s ability to benefit from and withstand the side effects of therapy. And that decision is usually based on a clinical assessment that is far more intuitive than it is scientific. (Source: Cancer Network)
Source: Cancer Network - February 9, 2013 Category: Cancer & Oncology Source Type: news

Pleural Nodules Discovered in 34-Year-Old Woman
A 34-year-old woman presents with pain in her left chest. Radiographic imaging shows the presence of nodules in the pleural surface. Surgical excision is performed. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - February 8, 2013 Category: Cancer & Oncology Source Type: news

Erlotinib Plus WBRT Effective for NSCLC Brain Metastases
The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer. (Source: Cancer Network)
Source: Cancer Network - February 7, 2013 Category: Cancer & Oncology Source Type: news

Long-Term Prostate Cancer Side Effects Similar With Surgery, Radiation
Men treated for localized prostate cancer have been found to have similar side effects 15 years after treatment (urinary incontinence, erectile dysfunction, bowel urgency) whether treated with surgery or radiation therapy, a new study says. (Source: Cancer Network)
Source: Cancer Network - February 7, 2013 Category: Cancer & Oncology Source Type: news